Journal of Neural Transmission

Papers
(The H4-Index of Journal of Neural Transmission is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Recent update on the heterogeneity of the Alzheimer’s disease spectrum55
Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders. Bioactive kynurenines and their analogues as neuroprotective agents—in celebration of 80th birthday of Professor Peter Ried55
Dystonia updates: definition, nomenclature, clinical classification, and etiology46
Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration42
Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity42
Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials40
Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease40
Impact of the COVID-19 lockdown on screen media use in patients referred for ADHD to child and adolescent psychiatry: an introduction to problematic use of the internet in ADHD and results of a survey39
Language in autism: domains, profiles and co-occurring conditions38
Contemporary functional neuroanatomy and pathophysiology of dystonia36
Viruses, parkinsonism and Parkinson’s disease: the past, present and future35
ADHD at the workplace: ADHD symptoms, diagnostic status, and work-related functioning33
Neuronal intranuclear inclusion disease: recognition and update31
Glucocerebrosidase mutations and Parkinson disease30
A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease30
Emerging and converging molecular mechanisms in dystonia30
The brain-first vs. body-first model of Parkinson’s disease with comparison to alternative models30
A brief history of brain iron accumulation in Parkinson disease and related disorders28
From the tyrosine hydroxylase hypothesis of Parkinson’s disease to modern strategies: a short historical overview26
The heterogeneity of Parkinson’s disease26
Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice26
COVID-19 outcomes of 10,881 patients: retrospective study of neurological symptoms and associated manifestations (Philippine CORONA Study)25
The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson’s disease25
SARS-CoV-2 and neurodegenerative diseases: what we know and what we don’t24
GBA-associated PD: chances and obstacles for targeted treatment strategies24
0.064222097396851